Fibrinogen is one of the first coagulation factors to reach critically low levels due to consumption or loss during major trauma, surgery and postpartum haemorrhage (PPH). Depending on the strategy of volume resuscitation, it is often further diluted. Fibrinogen is also reduced (hypofibrinogenaemia), not detectable (afibrinogenaemia) and/or non-functional (dysfibrinogenaemia) in patients with congenital fibrinogen deficiencies. Since fibrinogen deficiencies are known to be associated with an increased risk of excessive bleeding and mortality, treatment involves fibrinogen replacement. Fibrinogen replacement therapies include fresh frozen plasma (FFP), cryoprecipitate and fibrinogen concentrate (FCH), which has been shown to be at least as effective as cryoprecipitate.
Fibrinogen concentrate is at least as effective as cryoprecipitate for treating fibrinogen deficiency; however, practical and safety differences exist.
Here, we highlight clinical trial data on fibrinogen replacement therapies for different clinical settings and introduce practical considerations comparing safety, storage and speed of delivery.
Discover why fresh frozen plasma (FFP) is the most commonly used source of coagulation factor replenishment.
Find out why cryoprecipitate is a standard treatment in many countries in order to replenish fibrinogen in cases of acquired fibrinogen deficiency.
Discover information about fibrinogen concentrate and find out how it is obtained.
Here we compare the practicalities such as economical value, safety and preparation for fibrinogen replacement therapies.
Alternatively login via
Back to epgonline.org